Summary:
This grant opportunity, funded by the National Institutes of Health (NIH) under the National Institute on Drug Abuse (NIDA), aims to leverage artificial intelligence (AI) and polypharmacology to develop new and improved medications for substance use disorders (SUDs). The grant supports non-clinical research using AI tools and experimental assays to identify and develop pharmacotherapeutics with lower toxicity and higher efficacy for treating SUDs. Clinical trials are not allowed under this specific grant.
Sponsor:
National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Eligibility:
- Public and private non-profit organizations, such as universities, colleges, hospitals, and other research institutions located in the United States or its territories.
- For-profit organizations are eligible only if they collaborate with a non-profit partner.
- Principal Investigator (PI) with expertise in relevant fields like AI/machine learning, pharmacology, and SUD research.
- A strong research team with demonstrated experience in AI and/or drug discovery.
Benefits:
- Receive funding to conduct research utilizing AI and polypharmacology for SUD treatment development.
- Contribute to advancing the field of SUD medication development with innovative and potentially breakthrough discoveries.
- Gain recognition for your research and expertise in this crucial area of public health.
- Potential for future funding opportunities based on the success of your project.
Deadline:
July 25, 2024.